Otsuka Holdings (4578) · InitiativeEnd of U.S. Sales and Impairment of Related Assets
Commercialization of the digital medicine “Abilify MyCite”
First written in FY2017. . Latest entry: FY2024.
2entries
8years
0from disclosures
How it moved
Same theme, other companies
Commercialization and discontinuation of sales of the digital medicine “Abilify MyCite”A theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024End of U.S. Sales and Impairment of Related AssetsAnnual report
「The profitability of assets related to the digital medicine business declined due to the decision to end U.S. sales of Abilify MyCite and other factors. Accordingly, nearly all property, plant and equipment related to the business and the carrying amount of intangible assets were reduced to a recoverable amount of zero, representing value in use, and an impairment loss of ¥11,119 million was recognized.」
For the digital medicine described in FY2017 as having been successfully commercialized, the disclosure records the decision to end U.S. sales and the impairment of related assets. - FY2017First statedAnnual report
「The healthcare field is also pursuing new technologies. The Otsuka Group successfully commercialized the world's first digital medicine, Abilify MyCite®.」
The successful commercialization of a digital medicine is described for the first time as a specific example of pursuing new technologies and commercialization.